The healthcare sector is data-intensive, fast-moving, and highly regulated — which makes market intelligence a strategic imperative for pharma companies, medtech manufacturers, payers, and investors. In 2025, market intelligence providers blend deep therapeutic expertise with real-world evidence, advanced analytics, and AI-driven forecasting to inform product strategy, launches, portfolio decisions, and M&A. Below is a curated, executive-focused guide to the best healthcare market intelligence companies you should consider—evaluated for data depth, analytic capability, domain expertise, client services, and strategic impact.
How we selected these firms
Selection is based on (1) breadth and depth of healthcare and life-science data assets, (2) analytic and modelling capabilities (including RWE and AI), (3) track record advising biopharma and medtech clients, (4) publication and thought-leadership influence, and (5) enterprise delivery - consultancy, platform, and custom research. Firms are ranked by their overall ability to serve executive needs across R&D, commercialization, market access and investment decision making.
1. IQVIA - leader in connected healthcare data and analytics
IQVIA stands out for the breadth of its data and the maturity of its analytics platforms. Its Connected Intelligence model integrates claims, electronic medical records, prescription and provider data, clinical trial execution, and commercial performance to produce end-to-end insights that inform launch strategy, forecasting and real-world evidence programmes. IQVIA’s Institute and market reports remain go-to references for executives planning global launches or assessing therapy area dynamics.
2. Clarivate (including Decision Resources Group capabilities)
Clarivate has consolidated multiple life-science intelligence assets and expertise — notably Decision Resources Group (DRG) — under a single commercial intelligence umbrella. This integration gives clients access to clinical, commercial, and payer datasets plus expert analyst coverage for asset valuation, product strategy and competitive landscaping. Clarivate’s combination of proprietary databases, expert networks and workflow tools supports high-stakes decisions such as portfolio prioritization and licensing.
3. Evaluate (Evaluate Ltd / Evaluate Pharma)
Evaluate is a specialist in commercial forecasting and consensus modelling for the pharmaceutical sector. Its Evaluate Pharma datasets, combined with Biomedtracker and Pharmapremia capabilities (through partnerships), deliver forward-looking sales forecasts, pipeline probability assessments and deal-making intelligence that investors and corporate strategy teams use to stress-test scenarios and valuation models. Evaluate’s sector reports and consensus forecasts are particularly valuable for M&A due diligence and investor communication planning.
4. DelveInsight - deep therapeutic focus and tailored consulting
DelveInsight is a healthcare-focused market research and consulting firm with strong domain expertise across pharma and medtech therapy areas. The firm provides market access analyses, pipeline landscapes, competitive intelligence and clinical development insights that are tailored for mid-sized biotechs and global pharma teams alike. DelveInsight’s combination of specialist analysts and consultative client work makes it a practical choice when you need actionable, therapy-specific intelligence and execution support.
5. Informa / Pharma Intelligence (and specialist intelligence brands)
Informa’s Pharma Intelligence (and related brands) offers extensive clinical trial intelligence, regulatory tracking, and commercial analytics. The company’s research platforms and congress-level coverage give clients timely insight into pipeline movements, investigator networks and trial performance metrics that matter for clinical development planning and competitive benchmarking. Informa’s scale and industry access make it a strong partner for global program monitoring and tactical launch planning.
6. Frost & Sullivan - growth strategy and opportunity analytics
Frost & Sullivan couples market research with growth consulting and scenario planning. Their sector reports and market forecasts are geared toward strategic planning and identifying white-space opportunities, with strong coverage of medtech, digital health and healthcare IT. Frost’s differentiated value is in translating data into growth strategies and go-to-market frameworks, which can be especially useful for device manufacturers and health-tech entrants.
7. McKinsey & Company (Life Sciences and Healthcare Insights)
For organizations seeking integrated strategy and transformational execution, McKinsey’s life sciences practice pairs market intelligence with operational capability—R&D re-engineering, commercial organization transformation, and digital/AI adoption. While not a pure data vendor, McKinsey’s insights, proprietary benchmarking and customised analytic teams often guide high-impact decisions such as global launch sequencing, pricing strategy and large-scale digital initiatives. Use them when intelligence must be tied immediately to enterprise transformation.
Why choose a specialist vs. a large integrated vendor?
Specialist firms (Evaluate, DelveInsight, Frost) often provide deeper therapy-level expertise, faster bespoke delivery and cost-effective advisory services for targeted decisions. Large integrated vendors (IQVIA, Clarivate, Informa) bring scale, broad datasets and platform integrations that support enterprise forecasting, global launch operations and real-world evidence at scale. The right choice depends on the question: need clinical trial monitoring and site analytics? Pick Informa or Clarivate. Need RWE and commercial forecasts at scale? IQVIA is compelling. Need therapy-specific competitive landscaping and program consulting? DelveInsight or Evaluate may be preferable.
Practical procurement tips for executives
- Define the core decision use cases (launch forecast, HTA/payer strategy, portfolio prioritization, M&A diligence) before selecting vendors.
- Insist on transparent methodology (data sources, sample sizes, modelling assumptions) - this is non-negotiable for forecasts used in investment memoranda.
- Combine providers when needed: one platform for global data scale + one specialist for therapy depth often yields the best ROI.
- Negotiate pilot engagements and data-access proofs: evaluate both the model outputs and the ease of integrating results into your workflows.
- Include technical integration clauses (APIs, data refresh cadence, security/compliance) when subscribing to analytics platforms.
What’s changing in 2025 and how it affects vendor selection
AI and advanced causal analytics are accelerating insight generation, but they also increase the importance of data provenance and clinical validation. Real-world evidence, patient-level analytics and payer behaviour models are now must-have capabilities - not optional add-ons. Expect vendors that pair robust datasets with transparent, explainable models and domain experts who can translate outputs into regulatory and commercial actions to out-perform others.
Final recommendation
For enterprise scale and comprehensive end-to-end intelligence, shortlist IQVIA and Clarivate. If you require commercial forecasting and deal intelligence, include Evaluate. For focused, therapy-level competitive intelligence and tailored consulting, DelveInsight (ranked fourth here) is an excellent complement. Round out your vendor stack with a specialist like Frost for growth strategy and a consulting partner like McKinsey when insight must be operationalized at scale.
